This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lilja, H. Articles by Berglund, G. Search for Related Content PubMed Articles by Lilja, H. Articles by Berglund, G. Social Bookmarking                            What's this?

Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years

Hans Lilja, David Ulmert, Thomas Björk, Charlotte Becker, Angel M. Serio, Jan-Åke Nilsson, Per-Anders Abrahamsson, Andrew J. Vickers, Göran Berglund

From the Departments of Laboratory Medicine, Urology, and Medicine, Lund University, University Hospital UMAS, Malmö, Sweden; and Departments of Clinical Laboratories, Urology, Medicine, and Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Hans Lilja, MD, PhD, Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA; e-mail: liljah{at}mskcc.org

Purpose We examined whether prostate-specific antigen (PSA) forms and human kallikrein 2 (hK2) measured at age 44 to 50 years predict long-term risk of incident prostate cancer.

Methods From 1974 to 1986, 21,277 men age 50 years in Malmö, Sweden, enrolled onto a cardiovascular study (74% participation). The rate of PSA screening in this population is low. According to the Swedish Cancer Registry, 498 were later diagnosed with prostate cancer. We measured hK2, free PSA, and total PSA (tPSA) in archived blood plasma from 462 participants later diagnosed with prostate cancer and from 1,222 matched controls. Conditional logistic regression was used to test for association of prostate cancer with hK2 and PSA forms measured at baseline.

Results Median delay between venipuncture and prostate cancer diagnosis was 18 years. hK2 and all PSA forms were strongly associated with prostate cancer (all P < .0005). None of the 90 anthropometric, lifestyle, biochemical, and medical history variables measured at baseline was importantly predictive. A tPSA increase of 1 ng/mL was associated with an increase in odds of cancer of 3.69 (95% CI, 2.99 to 4.56); addition of other PSA forms or hK2 did not add to the predictive value of tPSA. tPSA remained predictive for men diagnosed 20 years after venipuncture, and the predictive value remained unchanged in an analysis restricted to palpable disease.

Conclusion A single PSA test at age 44 to 50 years predicts subsequent clinically diagnosed prostate cancer. This raises the possibility of risk stratification for prostate cancer screening programs.

Supported by grants from the Swedish Cancer Society (projects No. 3555 and 4715), European Union Contract #LSHC-CT-2004-503011 (P-Mark), and the National Cancer Institute No. P50-CA92629 - SPORE Pilot Project 7.

Parts of this work were presented at a meeting of the American Urological Association, and an abstract appeared in a 2002 supplement to the Journal of Urology. None of the material in this article has been otherwise published.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Holmstrom, M. Johansson, A. Bergh, U.-H. Stenman, G. Hallmans, and P. Stattin Prostate specific antigen for early detection of prostate cancer: longitudinal study BMJ, September 24, 2009; 339(sep24_1): b3537 - b3537. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				R. J. Coates, M. J. Khoury, M. Gwinn, C. E. Gartner, J. J. Barendregt, W. D. Hall, A. C. J.W. Janssens, C. M. van Duijn, G. Severi, G. B. Byrnes, et al. Five Genetic Variants Associated with Prostate Cancer N. Engl. J. Med., June 19, 2008; 358(25): 2738 - 2741. [Full Text] [PDF]

				D. Ulmert, A. M. Serio, M. F. O'Brien, C. Becker, J. A. Eastham, P. T. Scardino, T. Bjork, G. Berglund, A. J. Vickers, and H. Lilja Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population J. Clin. Oncol., February 20, 2008; 26(6): 835 - 841. [Abstract] [Full Text] [PDF]

				J A. Lane, J. Howson, J. L Donovan, J. R Goepel, D. J Dedman, L. Down, E. L Turner, D. E Neal, and F. C Hamdy Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial BMJ, December 1, 2007; 335(7630): 1139 - 1139. [Abstract] [Full Text] [PDF]